0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis carinii Pneumonia

DREW J. WINSTON, M.D.; WILLIAM K. LAU, M.D.; ROBERT PETER GALE, M.D., Ph.D.; and LOWELL S. YOUNG, M.D.
[+] Article and Author Information

Grant support: by a Research Grant from Hoffmann-LaRoche, Inc. , Nutley, New Jersey; Grants CA-23175 and CA-15688 from the National Cancer Institute; Grant HB-62971 from the National Heart, Lung, and Blood Institute; and Grant AI-15332 from the National Institute of Allergy and Infectious Diseases. Dr. Gale is a Scholar of the Leukemia Society of America.

▸Requests for reprints should be addressed to Drew J. Winston, M.D.; Division of Infectious Diseases, UCLA Center for the Health Sciences; Los Angeles, CA 90024.


Los Angeles, California


© 1980 American College of PhysiciansAmerican College of Physicians


Ann Intern Med. 1980;92(6):762-769. doi:10.7326/0003-4819-92-6-762
Text Size: A A A
This excerpt has been provided in the absence of an abstract.

Intravenous trimethoprim-sulfamethoxazole therapy was evaluated in 11 consecutive patients with documented Pneumocystis carinii pneumonia and the results compared to those from previously published studies of trimethoprim-sulfamethoxazole therapy for P. carinii pneumonia. Although six patients needed mechanical ventilation, intravenous therapy was successful in seven of 11 patients (64%), and seven of nine patients (78%) receiving 4 or more days of intravenous trimethoprim-sulfamethoxazole therapy were cured. Side effects occurred in two patients (skin rash in one, nausea and vomiting in one). A review of 80 reported cases of confirmed P. carinii pneumonia initially treated with trimethoprim-sulfamethoxazole alone revealed response rates of 67.5% in all treated patients and 85.5% in patients treated for 9 or more days. The clinical response was similar in adults (63.2%) and children (68.9%). Side effects were noted in only 11 of 80 patients (13.8%). Compared to pentamidine, trimethoprim-sulfamethoxazole has a narrower toxic-therapeutic ratio and should be preferred treatment for P. carinii pneumonia in adults as well as children.

...

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)